• KORU Medical Systems posted Q2 net revenues up 18.2% to $12 million, driven by 12.4% domestic core growth to $8 million.
• International core net revenues climbed 59.1% to $3.47 million, supported by distributor purchases tied to pre-filled syringe conversions.
• GAAP net income swung to $252,449, versus a prior-year loss; GAAP gross margin widened 1.6 percentage points to 65.1%.
• Acquired a connected monitoring technology asset; withdrew its U.S. 510(k) application for FreedomEDGE with Phesgo and shifted oncology focus to higher-volume molecules.
• Updated 2026 guidance: net revenues of $47.5 million-$48.5 million, gross margin of 62%-64%, positive adjusted EBITDA, year-end cash above $7.5 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. KORU Medical Systems Inc. published the original content used to generate this news brief on August 05, 2026, and is solely responsible for the information contained therein.